非小细胞肺癌的靶向治疗现状与进展  

Current status and progress of targeted therapy for non-small cell lung cancer

作　　者：马靖潇 马春强 范雯雯 赵秀娟 彭效祥 MA Jingxiao;MA Chunqiang;FAN Wenwen;ZHAO Xiujuan;PENG Xiaoxiang(Department of Clinical Laboratory,Affiliated Hospital of Shandong Second Medical University,Weifang 261031,China;School of Medical Laboratory,Shandong Second Medical University)

机构地区：[1]山东第二医科大学附属医院检验科,山东潍坊261031 [2]山东第二医科大学医学检验学院

出　　处：《山东第二医科大学学报》2024年第6期464-470,共7页Journal of Shandong Second Medical University

基　　金：潍坊市科技发展计划项目(项目编号:2023YX039)。

摘　　要：肺癌是中国最常见的原发性恶性肿瘤,主要分为小细胞肺癌和非小细胞肺癌(NSCLC),后者占85%。本研究探讨了NSCLC的病因、治疗策略及靶向治疗的最新进展。对靶向治疗中针对特定基因突变患者应用靶向药物抑制剂的效果进行了分析,结果显示分子靶向治疗可显著延长患者的生存期。因此,个体化治疗已逐渐成为肺癌管理的新模式,突出了分子靶向治疗的重要性,为肺癌的临床治疗提供了新的方向和依据。Lung cancer is the most prevalent primary malignant tumor in China,which is mainly categorized into small cell lung cancer and non-small cell lung cancer(NSCLC),with NSCLC accounting for 85%.This study delves into the etiology,treatment strategies,and the latest progress in targeted therapy for NSCLC.Through an analysis of the efficacy of targeted drug inhibitors administered to patients with specific gene mutations in the context of targeted therapy,it has been demonstrated that molecular targeted therapy can significantly prolong the survival time of patients.Consequently,personalized treatment has gradually emerged as a new paradigm for lung cancer management,underlining the significance of molecular targeted therapy and offering novel directions and a basis for the clinical treatment of lung cancer.

关 键 词：非小细胞肺肿瘤 分子靶向治疗 突变 治疗 进展 

分 类 号：R734.2[医药卫生—肿瘤]